We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current CRL market cap is 8.55B. The company's latest EPS is USD 0.4341 and P/E is 385.35.
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 1.01B | 1.01B | 1.03B | 1.01B | 1B |
| Operating Income | 132.92M | 133.94M | 163.71M | 97.39M | -167.69M |
| Net Income | 187.08M | 67.33M | 89.99M | 79.38M | -214.5M |
| Year End 28 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 2.92B | 3.54B | 3.98B | 4.13B | 4.05B |
| Operating Income | 432.73M | 589.86M | 650.98M | 617.26M | 227.35M |
| Net Income | 364.3M | 390.98M | 486.23M | 474.62M | 22.2M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 8.2B | 8.15B | 7.95B | 8B | 7.53B |
| Total Liabilities | 4.54B | 4.45B | 4.18B | 4.18B | 4.02B |
| Total Equity | 3.6B | 3.65B | 3.73B | 3.79B | 3.47B |
| Year End 28 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 5.49B | 7.02B | 7.6B | 8.2B | 7.53B |
| Total Liabilities | 3.35B | 4.43B | 4.58B | 4.54B | 4.02B |
| Total Equity | 2.12B | 2.54B | 2.98B | 3.6B | 3.47B |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 683.9M | 129.89M | 323.42M | 575.22M | 734.58M |
| Investing | -563.16M | -85.79M | -147.66M | -168.98M | -245.09M |
| Financing | -85.52M | 18.35M | -267.51M | -475.05M | -550.93M |
| Year End 28 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 546.58M | 760.8M | 619.64M | 683.9M | 734.58M |
| Investing | -601.54M | -1.44B | -607.92M | -563.16M | -245.09M |
| Financing | 47.25M | 672.6M | -42.4M | -85.52M | -550.93M |
| Market Cap | 8.55B |
| Price to Earnings Ratio | 385.35 |
| Price to Sales Ratio | 2.11 |
| Price to Cash Ratio | 43.96 |
| Price to Book Ratio | 2.44 |
| Dividend Yield | - |
| Shares Outstanding | 51.14M |
| Average Volume (1 week) | 1.09M |
| Average Volume (1 Month) | 1.41M |
| 52 Week Change | -38.85% |
| 52 Week High | 274.50 |
| 52 Week Low | 150.79 |
| Spread (Intraday) | 18.89 (11.18%) |
| Company Name | Charles River Laboratories International Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.criver.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
